MindownIn and Transcenta Announce Strategic Collaboration to Build a Digital Benchmark in Biopharmaceutical Manufacturing
On November 1, Mingdu Intelligent Cloud and Transcenta Holding signed a strategic cooperation agreement at Suzhou BioBAY. Through this partnership, the two parties will further deepen the integration of digital technologies to enhance the interoperability of Transcenta’s intelligent R&D, production, and warehouse logistics management platforms, jointly building an internationally leading digital factory for biopharmaceuticals.
Signing Ceremony Venue
At the ceremony, the two parties reached a consensus on future digital strategic cooperation and discussed the advanced experience of Zhejiang Province’s “Black Box” regulatory framework for pharmaceutical enterprises, with the aim of further empowering digitalization.
Ge Yafei, Chairman of Mingdu Intelligent Cloud, stated,Mingdu Intelligent Cloud has currently developed life science solutions covering the entire lifecycle, including intelligent R&D, intelligent manufacturing, and intelligent logistics, while also making strategic investments in cutting-edge algorithms and continuous manufacturing. We hope to deepen our collaboration with Transcenta Holding in digital transformation, building upon our existing partnership.
Dr. Qian Xueming, CEO of Transcenta Holding, stated,A warm welcome was extended to Mr. Ge, while higher expectations were expressed for enhancing the research and development and production capabilities of biopharmaceutical enterprises, with the aim of building a high-quality, partially unmanned digital factory that complies with regulatory requirements.
Dr. Ye Feng, Chief Operating Officer of Transcenta Holding, stated,Since partnering with Transcenta Holding, Mingdu Intelligent Cloud’s digital services—such as its PPM platform, data products, and Electronic Laboratory Notebook (ELN) system—have delivered substantial value to pharmaceutical R&D. The ongoing compliance consulting for pharmaceutical informatization further strengthens standardized and digitalized management across personnel, equipment, materials, methods, and environment (4M1E), ensuring full traceability throughout the R&D and production processes and comprehensively reducing compliance risks. The future collaboration on digital factory initiatives is highly anticipated, as both parties gradually build smart factories and establish an industry benchmark for digital intelligent manufacturing in China.
Signing Ceremony Group Photo
Previously, Transcenta Holding has engaged in multiple collaborations with Mingdu. Transcenta Holding has implemented Mingdu’s Laboratory Digital R&D Management Platform in its R&D projects, enabling comprehensive controllability and visibility throughout the drug development process. By achieving compliant and intelligent data capture, analysis, and management, the platform has provided a robust basis for scientific decision-making in Transcenta’s R&D efforts, significantly improving R&D efficiency and quality while effectively mitigating project risks.
Mingdu Zhiyun and Transcenta Holding’s shared insights into the future digitalization trends of the industry, coupled with the mutual trust established through their collaboration, have laid a solid foundation for their strategic partnership. Moving forward, this strategic cooperation with Transcenta will be built on the principles of “co-creation and win-win outcomes,” aiming to set a benchmark for digital innovation in the industry and fully support the Chinese pharmaceutical sector’s transition into a new era of digitalization and intelligence.
Transcenta Holding is a clinical-stage biopharmaceutical company with comprehensive, integrated capabilities in biologics discovery, research and development, process development, and manufacturing. On September 29, 2021, Transcenta Holding was listed on the Main Board of The Stock Exchange of Hong Kong Limited, with stock code: 06628.
Transcenta Holding is headquartered in Suzhou and has successfully established a global business footprint: it operates drug discovery, clinical, and translational research centers in Suzhou; a process and product development center along with a drug manufacturing base in Hangzhou; clinical development centers in Beijing, Shanghai, Guangzhou, and Princeton, USA; and external collaboration centers in Boston and Los Angeles, USA. Transcenta Holding’s development pipeline comprises nine novel therapeutic antibody molecules, covering indications in oncology, orthopedics, and nephrology.
Zhejiang Mingdu Intelligent Control Technology Co., Ltd. is a digital transformation service provider in the life sciences sector. Guided by its mission to “safeguard every medicine and protect every patient,” the company grows alongside pharmaceutical enterprises that adhere to stringent global compliance requirements, helping partners achieve digital and intelligent transformation. Mingdu has pioneered three innovative and specialized digital platforms in the industry: the MD-Xelerator SmartLab for intelligent drug R&D, the MindownIn Pharma platform for intelligent pharmaceutical manufacturing, and the Smart Biopharma platform. These platforms enable the company to provide partners with services spanning digital consulting, intelligent R&D, smart production, smart logistics, and compliance management. To date, Mingdu has served more than 100 leading domestic pharmaceutical companies, including Shanghai Pharmaceuticals Group, Livzon Group, China Resources Sanjiu, Yangtze River Pharmaceutical Group, Innovent Biologics, Transcenta Holding, Porton Pharma Solutions, Huahai Pharmaceutical, Beta Pharma, Huadong Medicine, NHU, Hongyun Huaning, Imabio, Humanwell Healthcare, E-Gen Biotech, Recbio, Pukang Biotechnology, 3SBio, Jiuxu Pharmaceutical, Saisheng Pharmaceutical, Dongfanghong Aerospace Biology, Chisen Pharmaceutical, Tianjin Institute of Pharmaceutical Research, Rundu Pharmaceutical, The United Laboratories International Holdings, and Kake Biotech.